Plexxikon's PLX3397 selected for I-SPY 2 breast cancer trial
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo subsidiary Plexxikon's oral small molecule PLX3397 joined the ranks of Amgen's trebananib and ganitumab as well as ganetespib from Synta Pharmaceuticals in the large, multi-arm, investigator-sponsored breast cancer clinical trial known as I-SPY 2.
You may also be interested in...
I-SPY 2 Helping To Normalize Adaptive Trial Designs
Publication in NEJM of results from Phase II of master protocol study of breast cancer combinations also helps build support for Bayesian statistics.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.